| ★ |  Obstetric manifestations in past and present antiphospholipid syndrome (APS) classification criteria | | 94 | — | |
| 18 |  Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 68 |
| 8 |  Recent advances in the treatment of inflammatory myopathies | | 618 | — | 71 |
| 14 |  Steroids in Relapsing Polychondritis | | 474 | — | 69 |
| 7 |  What is the added value of triple therapy in lupus nephritis? | | 438 | — | 72 |
| 19 |  Quality of life in Relapsing Polychondritis (RP) | | 412 | — | 68 |
| 4 |  Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 73 |
| 17 |  Thrombocytopenia in systemic lupus erythematosus (SLE) | | 249 | — | 68 |
| 9 |  Exercise as a non-pharmacological treatment adjunct to pharmacotherapy in systemic sclerosis. | | 222 | — | 71 |
| 10 |  Exercise in adult idiopathic inflammatory myopathies (IIMs) | | 188 | — | 71 |
| 6 |  The transition from benign to secondary Raynaud’s phenomenon | | 186 | — | 72 |
| 15 |  The Path to Better Treatments: A Patient-Friendly Guide to Sjögren’s Clinical Trials | | 171 | — | 69 |
| 20 |  Imaging in Relapsing Polychondritis (RP) | | 171 | — | 68 |
| 16 |  Everything you always wanted to know about Ehlers-Danlos Syndromes (EDS) – Part two | | 151 | — | 69 |
| 11 |  Tackling heterogeneity in Sjögren’s disease: the role of stratification and clustering | | 137 | — | 70 |
| 12 |  Vaccination in undifferentiated connective tissue disease (UCTD) | | 103 | — | 70 |
| 2 |  Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 74 |
| 13 |  Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies | | 64 | — | 69 |
| 3 |  Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 73 |
| 1 |  “Doctor, can you ask me…?” for connective tissue diseases patients | | 46 | — | 74 |
| 5 |  Genetic Testing in the Era of NGS: Lessons from the Hereditary Connective Tissue Disorders | | 35 | — | 72 |